FindTrial
Sign In

Effect of pressure reducing effect of Ripasudil eye drops in patients with high pressure within the eye

Evaluation of intraocular pressure lowering effect of 0.4% Ripasudil eye drops in patients with primary open angle glaucoma and ocular hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045191
Enrollment
55
Registered
2022-09-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H401- Open-angle glaucoma

Interventions

Intervention1: Patients with newly diagnosed primary open angle glaucoma and ocular hypertension, with central corneal thickness corrected IOP more than or equal to 22mmHg will be given Ripasudil eye

Sponsors

Sankara eye hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Central Corneal Thickness corrected intraocular pressure more than or equal to 22mmHg which includes primary open angle glaucoma and ocular hypertension

Exclusion criteria

Exclusion criteria: Patients with history of ocular trauma Patients with history of intraocular surgery Secondary glaucomas like angle closure glaucoma, neovascular glaucoma, pseudo-exfoliative glaucoma, pigmentary glaucoma Patients with pre-existing corneal diseases Pre-existing dry eye Patients with allergic conjunctivitis Pregnant and lactating women Patients who are not willing for follow up

Design outcomes

Primary

MeasureTime frame
To study the intraocular pressure lowering effect of 0.4% Ripasudil eye drops in patients with primary open angle glaucoma and ocular hypertensionTimepoint: Intraocular pressure is measured at baseline, 4 weeks, 12 weeks and 24 weeks—

Secondary

MeasureTime frame
To assess the incidence of side effects with RipasudilTimepoint: By assessing the side effects at 1st month, 3rd month and 6th month;To assess the IOP lowering effect of Ripasudil as a monotherapy or as an additive agentTimepoint: By comparing IOP at presentation (baseline) and at 1st month, 3rd months, 6th months;To assess the requirement of additional lubricants to continue RipasudilTimepoint: By assessing the side effects at 1st month, 3rd month and 6th month;To assess the requirement of additional ocular hypotensive drug in those patients on Ripasudil therapyTimepoint: By comparing IOP at presentation (baseline) and at 1st month, 3rd months, 6th months—

Countries

India

Contacts

Public ContactDr Amritha Madhu

Sankara eye hospital, Shimoga

kamala13@gmail.com9480362192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026